Navigation Links
Hospira Announces U.S. Approval of Generic Docetaxel

LAKE FOREST, Ill., March 9, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of docetaxel. The medication is a generic version of Sanofi-Aventis's Taxotere®, and Hospira expects to launch the product later this month.

Hospira's docetaxel is approved for the treatment of a variety of cancers. In 2010, U.S. sales of Taxotere were approximately $1.2 billion.

Unlike original product formulations that require healthcare workers to take a two-step process prior to infusion, Hospira's docetaxel comes in a single-vial formulation that is designed to reduce the number of handling steps in the preparation of the product.

"Hospira's docetaxel will give U.S. cancer patients access to a high-quality, lower-cost alternative to the branded product, offers a differentiated delivery system designed to enhance caregiver safety, and reinforces Hospira's commitment to meet patient and caregiver needs in the oncology space," said Thomas Moore, president, U.S., Hospira.

Hospira will offer 20 mg, 80 mg and 160 mg vials of docetaxel at a 10 mg/mL concentration, the original concentration that customers have used safely for many years. Hospira already markets docetaxel in Europe and Australia.

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated presentations, several of which are proprietary, such as ADD-Vantage™ drug delivery system and iSecure™ prefilled syringes. Therapeutic segments include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the growth opportunities for generic specialty injectable products. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, legal, regulatory, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role
2. Hospira MedNet™ Portal Safety Software Benchmarking System Debuts at HIMSS
3. Hospira to Present at Upcoming Investor Conferences
4. Hospira Announces FDA Approval of Topotecan Injection
5. Hospira Reports Fourth-Quarter and Full-Year 2010 Results
6. Hospira to Host Conference Call for Fourth-Quarter 2010 Results and 2011 Projections
7. Hospira Launches Piperacillin and Tazobactam for Injection in the United States
8. Hospira Announces New Contracts in Effect with Novation for Infusion Pumps, Solutions and Equipment
9. Hospira to Host Conference Call for Third-Quarter 2010 Results
10. Hospira Receives TGA Approval for Nivestim™, Australias First Biosimilar Filgrastim
11. Hospira Japan Receives Approval for New Indication for Precedex IV™ 200ug
Post Your Comments:
(Date:10/13/2015)... China Jo-Jo Drugstores, Inc. (NASDAQ ... a leading China-based retail, wholesale and online distributor of ... and retail pharmacies, announced preliminary half year fiscal 2016 ... through , growing 438% year over year, ... China Jo-Jo,s online sales are principally ...
(Date:10/13/2015)...  XiMo AG ( Lucerne , ... Milpitas, California ) announced today the launch ... importance of metathesis chemistry was highlighted by the Nobel ... application. This industrially-relevant application has been utilized in the ... chemicals, and polymers. Georg Fráter , COO ...
(Date:10/12/2015)... -- Apheresis is an invasive process that ... and other components from whole blood. In this procedure, the ... an apheresis machine or a blood cell separator. The apheresis ... other blood components. A selected part of the blood is ... or the patient. It involves the use of devices and ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... "My friend's son suffers from eczema, and ... cheeks," said an inventor from Platteville, Colo. "I came up with this kit as ... the UNTOUCHABLE to prevent a child from rubbing or scratching his or her face. ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... platform, ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a technology ... innovative health programs and interventions via mobile devices that provide a framework for ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG ... Summit, GPUG Summit and NAVUG Summit are independent user conferences designed and led ...
(Date:10/13/2015)... ... 2015 , ... In an age where the cost of energy is rising, ... foot than in 2009. The Williamsport Regional Medical Center (WRMC) campus has grown 50 ... eight percent. , According to Facilities Management Administrative Director Dieter Reichmann, this is ...
(Date:10/13/2015)... ... 2015 , ... e-con Systems Inc., a leading embedded design services company specializing ... first RGB-IR pixel format camera with a USB 3.0 interface and e-CAM40_CUMI4682_MOD, ... UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 - a 4-megapixel image ...
Breaking Medicine News(10 mins):